The DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index.
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ApoE is strongly associated with the amount of fibrillar amyloid that deposits into plaques (28).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [28]
In the citing paper
“In addition to isoform status, it appears that the amount of apoE also plays a role in determining the extent of Aβ accumulation in the brain.”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Bales et al., 1997
In the citing paper
“Initial studies clearly indicated that the deletion of the endogenous murine Apoe gene causes a dramatic decrease in fibrillar and total Aβ deposition in APP transgenic mouse models (Bales et al., 1997).”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Bales et al., 1997
In the citing paper
“Previous studies demonstrated that the lack of apoE led to a dramatic decrease of amyloid deposition in APP transgenic mouse models (Bales et al., 1997; Holtzman et al., 2000b).”
From Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance (2009) · cites this paper as Bales et al., 1997
In the citing paper
“Previous studies demonstrated that the absence of apoE leads to a dramatic decrease in the levels of fibrillar Aβ deposits in APP transgenic mouse models (Bales et al., 1999; Bales et al., 1997; Holtzman et al., 2000a; Holtzman et al., 2000b).”
From Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance (2009) · cites this paper as Bales et al., 1997
In the citing paper
“Later, in vivo studies demonstrated that the lack of apoE led to a dramatic reduction of fibrillar Aβ deposition in APP transgenic mouse models (Bales et al., 1999; Bales et al., 1997; Holtzman et al., 2000a; Holtzman et al., 2000b).”
From Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance (2009) · cites this paper as Bales et al., 1997
In the citing paper
“Reducing ApoE in mouse models of amyloidosis greatly reduces plaque formation (7, 8, 33, 34).”
From The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Aβ amyloidosis (2015) · cites this paper as [33]
In the citing paper
“Both genetic deletion and pharmacological reduction of APOE reduced Aβ deposition in mouse models of AD. 3 , 4 , 5 , 6 , 7 , 8 , 9”
From Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [3]
In the citing paper
“Notably, deletion of Apoe reduces amyloid deposition in transgenic mouse models of AD. 3 , 4”
From Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [3]
In the citing paper
“Our findings remain consistent with the effects of apoE knock-out noted in several AD Tg mouse models, where lack of apoE was associated with absence of fibrillar Aβ deposits and prevented neurodegeneration [13,29,31,32].”
From Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice (2014) · cites this paper as [31]
In the citing paper
“Independent of apoE isoform, the amount of apoE in the brain appears to be critical for determining the extent of amyloid deposition [25,26].”
From Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling (2012) · cites this paper as [25]
In the citing paper
“ApoE gene deletion in APP transgenic mice leads to dramatically decreased amyloid plaques without affecting Aβ production (Bales et al., 1997).”
From Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms (2014) · cites this paper as Bales et al., 1997
In the citing paper
“The pivotal role of ApoE in brain Ab accumulation was confirmed by showing a marked reduction in Ab plaque and CAA deposits associated with the Apoe gene knockout (KO) in AD transgenic (Tg) mice.14”
From Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration (2013) · cites this paper as [14]
In the citing paper
“Similar effects of the ApoE KO were previously reported in APP V717F and APP SW lines, representing more latent models of Ab pathology in which thioflavin-S detects the first plaques around the age of 1 year.14,55”
From Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration (2013) · cites this paper as [14]
In the citing paper
“Reducing ApoE levels is generally protective in AD models1,4–6.”
From Decreased lipidated ApoE‐receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes (2025) · cites this paper as [4]
In the citing paper
“Previous studies showed that apoE is co-deposited in senile plaques and plays a crucial role in fibrillar plaque formation (23, 24).”
From APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [23]
In the citing paper
“In amyloid precursor proteineexpressing transgenic mice, deletion of mouse apoE gene inhibits development of fibrillar amyloid plaques [80,81].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [80]
In the citing paper
“ApoE strongly regulates brain amyloid-β (Aβ) deposition in a dose- and isoform-dependent manner (E4>E3>E2) (Bales et al., 1997; Holtzman et al., 2000; Schmechel et al., 1993).”
From Overexpressing low‐density lipoprotein receptor reduces tau‐associated neurodegeneration in relation to apoE‐linked mechanisms (2021) · cites this paper as Bales et al., 1997
In the citing paper
“APP transgenic mice lacking endogenous mouse apoE display a significant decrease of amyloid pathology”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Bales et al 1997
In the citing paper
“apoE-deficient APP transgenic mice display virtually no fibrillar Aβ deposits nor neuritic degeneration”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Bales et al 1997
In the citing paper
“Initial studies using the PDAPP and Tg2576 APP transgenic mouse models that develop Aβ deposition demonstrated that the lack of murine apoE resulted in a significant decrease in Aβ deposition, along with an almost complete lack of true amyloid plaques and neuritic dystrophy (Bales et al., 1997; Holtzman et al., 2000; Holtzman et al., 1999).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Bales et al., 1997
In the citing paper
“Data from transgenic mouse models produced more conflicting results with impaired plaque deposition seen in mice lacking murine APOE (Bales et al., 1997; Holtzman et al., 2000), but also in animals overexpressing the human APOE3 or APOE4 isoforms (Holtzman et al., 1999).”
From The Pro-Neurotrophin Receptor Sortilin Is a Major Neuronal Apolipoprotein E Receptor for Catabolism of Amyloid-β Peptide in the Brain (2013) · cites this paper as Bales et al., 1997
In the citing paper
“Murine Apoe deletion reduced Aβ deposition in various transgenic APP mouse models (Bales, Verina et al. 1997, Bales, Verina et al. 1999, Holtzman, Fagan et al. 2000, Irizarry, Cheung et al. 2000, Ulrich, Ulland et al. 2018)”
From SORLA up-regulation suppresses pathological effects in aged tauopathy mouse brain (2026) · cites this paper as Bales, Verina et al. 1997
In the citing paper
“ApoE has a major impact on the generation of amyloid deposits in the AD mouse brain and deletion of ApoE in most AD mouse models significantly inhibits amyloid plaque formation [6], [7], [8].”
From Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model (2011) · cites this paper as [8]
In the citing paper
“APP transgenic mice deficient for ApoE show a dramatic decrease in fibrillary amyloid deposits [5], [6], [7], [8], [9].”
From Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model (2011) · cites this paper as [8]
In the citing paper
“Total body apoE knockout as well as astrocyte specific ApoE knockout results in markedly decreased fibrillar amyloid deposition and in less compact Aβ plaques as well as decreasing neuronal loss and reactive gliosis in a tauopathy model [96, 99, 100].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [100]
In the citing paper
“In addition, the strongest genetic risk factor for LOAD, apolipoprotein E, APOE, in large part appears to increase risk via influencing Aβ seeding and clearance”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Bales et al., 1997
In the citing paper
“To date, substantial evidence has demonstrated ApoE affects amyloid-β deposition in a dosage and isoform-specific fashion (ApoE4>ApoE3>ApoE2)96–100”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [96]
In the citing paper
“Transgenic mouse studies confirmed that ApoE was necessary for the formation of fibrillar amyloid plaques and CAA [4, 5, 41, 61], however they also identified important differences between mouse and human ApoE.”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [5]
Citations
Cites
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Self-citationSpontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein E
Zhang, S. H., Reddick, R. L., Piedrahita, J. A., & Maeda, N. (1992) · Science · doi:10.1126/science.1411543 · Cited by 2,237
Apolipoprotein E polymorphism and Alzheimer's disease
Poirier, J., Bertrand, P., Poirier, J., Kogan, S., Gauthier, S., Poirier, J., Gauthier, S., Davignon, J., Bouthillier, D., & Davignon, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91705-q · Cited by 1,108
Ma, J., Yee, A., Brewer, H. B., Das, S., & Potter, H. (1994) · Nature · doi:10.1038/372092a0 · Cited by 871
Normal and Abnormal Biology of the Beta-Amyloid Precursor Protein
Selkoe, D. J. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.002421 · Cited by 834
Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701
Apolipoprotein E and Alzheimer disease.
Strittmatter, W. J., & Roses, A. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4725 · Cited by 701
(1997) · doi:10.1073/pnas.94.4.1550 · Cited by 535
Human apolipoprotein E: the Alzheimer's disease connection
Weisgraber, K. H., & Mahley, R. W. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.13.8940294 · Cited by 333
Hyman, B. T., West, H. L., Rebeck, G. W., Buldyrev, S. V., Mantegna, R. N., Ukleja, M., Havlin, S., & Stanley, H. E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3586 · Cited by 212
Flagged first, then by citations
1 of the 14 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Kim, K.S. et al. Neurosci. Res. Comm. 51, 113–122 (1990).
- Brown, B.M. & Hettmansperger, T.P. J. Am. Stat. Assoc. 91, 1668–1675 (1996).
Cited by
Sorted by citations
Items 401–500 of 829
NAKAI, T., Yamada, K., & Mizoguchi, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115549 · Cited by 53
Thal, D. R., Capetillo-Zarate, E., Schultz, C., Rüb, U., Saido, T. C., Yamaguchi, H., Haass, C., Griffin, W. S. T., Del Tredici, K., Braak, H., et al. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1053-1 · Cited by 50
Biochemical analysis of cell-derived apoE3 particles active in stimulating neurite outgrowth
Demattos, R. B., Rudel, L. L., & Williams, D. L. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31622-9 · Cited by 48
Prevention and Reduction of AD‐type Pathology in PDAPP Mice Immunized with Aβ1–42
Games, D., Bard, F., Grajeda, H., Guido, T., Khan, K., Soriano, F., Vasquez, N. J., Wehner, N., Johnson‐Wood, K., Yednock, T. A., et al. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06936.x · Cited by 50
Choi, J., Gao, J., Kim, J., Hong, C., Kim, J., & Tontonoz, P. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad1904 · Cited by 49
Cui, Y., Huang, M., He, Y., Zhang, S., & Luo, Y. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.11.057 · Cited by 49
Cholesterol and Alzheimer's disease: A still poorly understood correlation
Ricciarelli, R., Canepa, E., Marengo, B., Marinari, U. M., Poli, G., Pronzato, M. A., & Domenicotti, C. (2012) · IUBMB Life · doi:10.1002/iub.1091 · Cited by 50
Panza, F., Solfrizzi, V., Frisardi, V., Imbimbo, B. P., Capurso, C. A., D’Introno, A., Colacicco, A. M., Seripa, D., Vendemiale, G., Capurso, A., et al. (2009) · Aging Clinical and Experimental Research · doi:10.1007/bf03327445 · Cited by 49
Reelin and apoE actions on signal transduction, synaptic function and memory formation
Rogers, J. T., & Weeber, E. J. (2008) · Neuron Glia Biology · doi:10.1017/s1740925x09990184 · Cited by 48
Is there a relation between APOE expression and brain amyloid load in Alzheimer's disease?
Lambert, J. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.048983 · Cited by 51
Wolozin, B. L., Brown, J. A., Theisler, C. M., & Silberman, S. (2004) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2004.tb00009.x · Cited by 49
Cholesterol, Aβ and Alzheimer's disease
Hartmann, T. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(01)00008-x · Cited by 49
Phagocytosis of Apoptotic Cells Is Specifically Upregulated in ApoE4 Expressing Microglia in vitro
Muth, C., Hartmann, A., Falla, D. S., Glatzel, M., & Krasemann, S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00181 · Cited by 47
Candidate Gene Association Studies in Sporadic Alzheimer’s Disease
Combarros, O., Alvarez-Arcaya, A., Sánchez-Guerra, M., Infante, J., & Berciano, J. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000058332 · Cited by 48
Wang, Y. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.06.018 · Cited by 47
ApoE4 inhibition of VMAT2 in the locus coeruleus exacerbates Tau pathology in Alzheimer’s disease
Kang, S. S., Ahn, E. H., Liu, X., Bryson, M., Miller, G. W., Weinshenker, D., & Ye, K. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02315-1 · Cited by 52
Leighty, R. E., Nilsson, L. N. G., Potter, H., Costa, D. A., Low, M. A., Bales, K. R., Paul, S. M., & Arendash, G. W. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2003.11.004 · Cited by 47
Self-citationAlzheimer Disease Therapeutics
Irizarry, M. C., & Hyman, B. T. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.10.923 · Cited by 49
Genes and susceptible loci of Alzheimer’s disease
Shastry, B. S., & Giblin, F. J. (1999) · Brain Research Bulletin · doi:10.1016/s0361-9230(98)00156-7 · Cited by 48
Tycko, B., Lee, J. H., Ciappa, A., Saxena, A. D., Li, C.-M., Lin, F., Arriaga, A., Stern, Y., Lantigua, R., Shachter, N. S., et al. (2004) · Archives of Neurology · doi:10.1001/archneur.61.9.1434 · Cited by 46
Alzheimer's disease: brain expression of a metabolic disorder?
Merlo, S., Spampinato, S. F., Canonico, P. L., Copani, A., & Sortino, M. A. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.05.005 · Cited by 50
Han, X. (2010) · Molecular Neurobiology · doi:10.1007/s12035-009-8092-x · Cited by 47
Altered membrane fluidity and lipid raft composition in presenilin-deficient cells
Grimm, M. O. W., Tschäpe, J., Grimm, H. S., Zinser, E. G., & Hartmann, T. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00682.x · Cited by 45
Lesuisse, C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.22.2525 · Cited by 45
Naidu, A., Xu, Q., Catalano, R., & Cordell, B. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03480-7 · Cited by 46
Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
McKee, C. A., Lee, J., Cai, Y., Saito, T., Saido, T. C., & Musiek, E. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-05862-z · Cited by 47
QUINN, C. M., KÅGEDAL, K., TERMAN, A., STROIKIN, U., BRUNK, U. T., JESSUP, W., & GARNER, B. (2004) · Biochemical Journal · doi:10.1042/bj20031352 · Cited by 36
Genetic Analysis of Vascular Factors in Alzheimer's Disease
Wakutani, Y., Kowa, H., Kusumi, M., YAMAGATA, K., Wada‐Isoe, K., Adachi, Y., Takeshima, T., Urakami, K., & Nakashima, K. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04820.x · Cited by 45
Alzheimer disease — when and why?
Price, D. L., Sisodia, S. S., & Borchelt, D. (1998) · Nature Genetics · doi:10.1038/1196 · Cited by 45
Recent Advances in the Genetics of Alzheimer's Disease
Levy‐Lahad, E., Tsuang, D. W., & Bird, T. D. (1998) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879801100202 · Cited by 46
DeMattos, R. B. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:255 · Cited by 55
Lord, A., Philipson, O., Klingstedt, T., Westermark, G. T., Hammarström, P., Nilsson, K. P. R., & Nilsson, L. N. G. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.01.052 · Cited by 46
Toxic amyloid-β oligomers induced self-replication in astrocytes triggering neuronal injury
Wang, W., Hou, T., Jia, L.-F., Wu, Q., Quan, M., & Jia, J. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.049 · Cited by 42
The prionoses and other conformational disorders
Wısnıewskı, T., Aucouturier, P., Soto, C. A., & Frangione, B. (1998) · Amyloid · doi:10.3109/13506129809003848 · Cited by 42
Helmond, Z. V., Miners, J. S., Kehoe, P. G., & Love, S. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00321.x · Cited by 44
Therapeutic options in Alzheimer’s disease
Moreira, P. I., Zhu, X., Nunomura, A., Smith, M. A., & Perry, G. L. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.6.897 · Cited by 44
Wısnıewskı, T., & Sadowski, M. J. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s2-s5 · Cited by 42
Molecular and Cellular Basis for Anti-Amyloid Therapy in Alzheimer Disease
Gandy, S., Martins, R. N., & Buxbaum, J. D. (2003) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200310000-00011 · Cited by 41
Allelic expression of APOE in human brain: Effects of epsilon status and promoter haplotypes
Bray, N. J., Jehu, L., Moskvina, V., Buxbaum, J. D., Dracheva, S., Haroutunian, V., Williams, J., Buckland, P. R., Owen, M. J., & O'Donovan, M. C. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh299 · Cited by 45
Mureşan, V., & Muresan, Z. L. (2009) · Future Neurology · doi:10.2217/fnl.09.54 · Cited by 41
Gandy, S., & Petanceska, S. S. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00031-4 · Cited by 40
Apolipoprotein E Genotype e2: Neuroprotection and Its Limits
Kim, H., Devanand, D. P., Carlson, S., & Goldberg, T. E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.919712 · Cited by 42
Chen, Y. L., Wang, L.-Y., Chen, Y., Gao, J. Y., Marshall, C., Cai, Z., Hu, G., & Xiao, M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.12.039 · Cited by 40
The Role of Apolipoprotein E Isoforms in Alzheimer’s Disease
Roda, A. R., Montoliu‐Gaya, L., & Villegas, S. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180740 · Cited by 41
Abdelhamid, M., Jung, C., Zhou, C., Abdullah, M., Nakano, M., Wakabayashi, H., Abe, F., & Michikawa, M. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191181 · Cited by 41
Therapeutic approaches for prion and Alzheimer's diseases
Wısnıewskı, T., & Sigurdsson, E. M. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.05919.x · Cited by 41
Wu, C.-W., Liao, P., Lin, C., Kuo, C.-J., Chen, S.-T., Chen, H., & Kuo, Y. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0809-1 · Cited by 40
Mulder, M., & Terwel, D. (1998) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000022429 · Cited by 40
Vrièze, F. W., Crook, R., Holmans, P., Kehoe, P. G., Owen, M. J., Williams, J. H., Roehl, K., Lahiri, D. K., Shears, S., Booth, J., et al. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00417-6 · Cited by 40
Monogenetic determinants of Alzheimer's disease: APP mutations
Goate, A. (1998) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050218 · Cited by 41
Chan, E. S., Shetty, M. S., Sajikumar, S., Chen, C., Soong, T. W., & Wong, B.-S. (2016) · Scientific Reports · doi:10.1038/srep26119 · Cited by 39
Multi-functional role of apolipoprotein E in neurodegenerative diseases
Islam, S., Noorani, A. A., Sun, Y., Michikawa, M., & Zou, K. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1535280 · Cited by 43
Metals and cholesterol: two sides of the same coin in Alzheimer’s disease pathology
Wong, B. X. W., Hung, Y. H., Bush, A. I., & Duce, J. A. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00091 · Cited by 41
Immunotherapeutic approaches for Alzheimer’s disease in transgenic mouse models
Wısnıewskı, T., & Boutajangout, A. (2009) · Brain Structure and Function · doi:10.1007/s00429-009-0236-2 · Cited by 39
Cellular Cofactors for Amyloid β-Peptide-Induced Cell Stress
Yan, S. D., Roher, A. E., Schmidt, A. M., & Stern, D. M. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65452-1 · Cited by 40
Petegnief, V., Saura, J., DeGregorio‐Rocasolano, N., & Paul, S. M. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00046-x · Cited by 39
Self-citationApolipoprotein E isoform-dependent effects on the processing of Alzheimer's amyloid-β
Chai, A. B., Lam, H. H. J., Kockx, M., & Gelissen, I. C. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158980 · Cited by 41
Association of ApoE and LRP mRNA levels with dementia and AD neuropathology
Akram, A. M., Schmeidler, J., Katsel, P., Hof, P. R., & Haroutunian, V. H. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.04.010 · Cited by 37
Molecular Pathology of Alzheimer’s Disease and Related Disorders
Ginsberg, S. D., Schmidt, M. L., Crino, P. B., Eberwine, J. H., Lee, V. M. ‐., & Trojanowski, J. Q. (1999) · Cerebral cortex · doi:10.1007/978-1-4615-4885-0_17 · Cited by 38
What transgenic mice tell us about neurodegenerative disease
Gurney, M. E. (2000) · BioEssays · doi:10.1002/(sici)1521-1878(200003)22:3 · Cited by 38
Rebeck, G. W., Cheung, B. S., Growdon, W. B., Deng, A., Akuthota, P., Locascio, J. J., Greenberg, S. M., & Hyman, B. T. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00602-3 · Cited by 38
Engineering Conformational Destabilization into Mouse Apolipoprotein E
Hatters, D. M., Peters-Libeu, C. A., & Weisgraber, K. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503910200 · Cited by 38
Fitz, N. F., Tapias, V., Cronican, A. A., Castranio, E. L., Saleem, M., Carter, A. Y., Lefterova, M. I., Lefterov, I. M., & Koldamova, R. P. (2015) · Brain · doi:10.1093/brain/awv293 · Cited by 38
Alzheimer's Disease and NQO1: Is there a Link?
Chhetri, J., King, A. E., & Gueven, N. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170203095802 · Cited by 38
Linck, L. M., Lin, D. S., Flavell, D. P., CONNOR, W. E., & Steiner, R. D. (2000) · American Journal of Medical Genetics · doi:10.1002/1096-8628(20000828)93:5 · Cited by 66
Genetically altered transgenic models of Alzheimer’s disease
Masliah, E., & Rockenstein, E. M. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6781-6_20 · Cited by 37
Ferguson, C. M., Hildebrand, S. R., Godinho, B. M. D. C., Buchwald, J. E., Echeverria, D., Coles, A. H., Grigorenko, A. P., Vangjeli, L., Sousa, J., McHugh, N., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13703 · Cited by 43
Rolyan, H., Feike, A. C., Upadhaya, A. R., Waha, A., Dooren, T. V., Haass, C., Birkenmeier, G., Pietrzik, C. U., LEUVEN, F. V., & Thal, D. R. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-010-0572-7 · Cited by 39
Fukuyama, R., Mizuno, T., Mori, S., Yanagisawa, K., Nakajima, K., & Fushiki, S. (2000) · European Neurology · doi:10.1159/000008157 · Cited by 36
Hopkins, P. C. R., Sáinz‐Fuertes, R., & Lovestone, S. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-102115 · Cited by 35
Passarella, D., Ciampi, S., Liberto, V. D., Zuccarini, M., Ronci, M., Medoro, A., Foderà, E., Frinchi, M., Mignogna, D., Russo, C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168921 · Cited by 38
Apolipoprotein E includes a binding site which is recognized by several amyloidogenic polypeptides
Baumann, M., Kallijärvi, J., Lankinen, H., Soto, C., & Haltia, M. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3490077 · Cited by 35
Potter, H. (1998) · Frontiers in bioscience · doi:10.2741/a290 · Cited by 35
Apolipoprotein E and Alzheimer Disease
Growdon, J. H. (1998) · Archives of Neurology · doi:10.1001/archneur.55.8.1053 · Cited by 34
LaDu, M. J., Stine, Narita, M., Getz, G. S., Reardon, C. A., & Bu, G. (2006) · Biochemistry · doi:10.1021/bi051765s · Cited by 36
Huang, L., Liu, X., Cheng, B., & Huang, K. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.01.007 · Cited by 34
Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease
Yang, Y., Keene, C. D., Peskind, E. R., Galasko, D. R., Hu, S., Cudaback, E., Wilson, A. M., Li, G., Yu, C., Montine, K. S., et al. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000207 · Cited by 35
Silva, S., Marto, J. M., Gonçalves, L., Almeida, A. J., & Vale, N. (2020) · Nanomaterials · doi:10.3390/nano10102089 · Cited by 34
Diet and Age Interactions with Regards to Cholesterol Regulation and Brain Pathogenesis
Uranga, R. M., & Keller, J. N. (2010) · Current Gerontology and Geriatrics Research · doi:10.1155/2010/219683 · Cited by 36
Neurohormonal Signaling Pathways and the Regulation of Alzheimer β-Amyloid Precursor Metabolism
Gandy, S. (1999) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(99)00166-6 · Cited by 32
Apolipoprotein E secreted by astrocytes forms antiparallel dimers in discoidal lipoproteins
Strickland, M. R., Rau, M. J., Summers, B., Basore, K., Wulf, J., Jiang, H., Chen, Y., Ulrich, J. D., Randolph, G. J., Zhang, R., et al. (2024) · Neuron · doi:10.1016/j.neuron.2023.12.018 · Cited by 28
Feng, B., Freitas, A. E., Gorodetski, L., Wang, J., Tian, R., Lee, Y. R., Grewal, A. S., & Zou, Y. (2021) · Science Advances · doi:10.1126/sciadv.abh2307 · Cited by 38
Genetic variants associated with neurodegenerative Alzheimer disease in natural models
Salazar, C., Valdivia, G., Ardiles, Á. O., Ewer, J., & Palacios, A. G. (2016) · Biological Research · doi:10.1186/s40659-016-0072-9 · Cited by 33
Nishida, K., Quantock, A. J., Dota, A., Choi-Miura, N.-H., & Kinoshita, S. (1999) · British Journal of Ophthalmology · doi:10.1136/bjo.83.10.1178 · Cited by 33
Cerebrospinal fluid apolipoprotein E concentration decreases after traumatic brain injury
Kay, A. D., Petzold, A., Kerr, M., Keir, G., Thompson, E. J., & Nicoll, J. A. R. (2003) · Journal of Neurotrauma · doi:10.1089/089771503321532824 · Cited by 33
Regulation of apolipoprotein E secretion in rat primary hippocampal astrocyte cultures
Cedazo-Mı́nguez, Á., Hamker, U., Meske, V., Veh, R. W., Hellweg, R., Jacobi, C., Albert, F., Cowburn, R. F., & Ohm, T. G. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00224-x · Cited by 34
Vincent, B., & Smith, J. D. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01643.x · Cited by 32
APOE ε variants increase risk of warfarin-related intracerebral hemorrhage
Falcone, G. J., Radmanesh, F., Brouwers, H. B., Battey, T. W. K., Devan, W. J., Valant, V., Raffeld, M. R., Chitsike, L., Ayres, A. M., Schwab, K. M., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000816 · Cited by 33
Overview on Rodent Models of Alzheimer's Disease
Dodart, J., & May, P. C. (2005) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0922s33 · Cited by 32
Alzheimer’s Disease in Man and Transgenic Mice
Turner, R. S. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64026-6 · Cited by 31
Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer’s disease
Gandy, S. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00125-2 · Cited by 32
Current anti-Alzheimer’s disease effect of natural products and their principal targets
Zhu, Y., Peng, L., Hu, J., Chen, Y., & Chen, F. (2019) · Journal of Integrative Neuroscience · doi:10.31083/j.jin.2019.03.1105 · Cited by 31
Opposing Roles of apolipoprotein E in aging and neurodegeneration
Hudry, E., Klickstein, J., Cannavo, C., Jackson, R., Muzikansky, A., Gandhi, S., Urick, D., Sargent, T., Wrobleski, L., Roe, A. D., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201900325 · Cited by 30
Molecular Pathogenesis and Interventional Strategies for Alzheimer’s Disease: Promises and Pitfalls
Bhute, S., Sarmah, D., Datta, A., Rane, P., Shard, A., Goswami, A., Borah, A., Kalia, K., Dave, K. R., & Bhattacharya, P. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00104 · Cited by 32
Zhang, Y., Gao, H., Zheng, W., & Xu, H. J. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105824 · Cited by 31
Sullivan, P. M., Mace, B. E., Estrada, J. C., Schmechel, D. E., & Alberts, M. J. (2008) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2008.03.011 · Cited by 30
Guix, F. X. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24526 · Cited by 30
Vidal, J., Verchere, C. B., Andrikopoulos, S., Wang, F., Hull, R. L., Cnop, M., Olin, K., LeBoeuf, R. C., O’Brien, K. D., Chait, A., et al. (2003) · Diabetologia · doi:10.1007/s00125-002-0984-5 · Cited by 30
Metadata
- Authors
- Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., Piccardo, P., Ghetti, B., & Paul, S. M.
- Affiliations
- Eli Lilly (United States) (US)
- Indiana University School of Medicine (US)
- Philipps University of Marburg (DE)
- Venue
- Nature Genetics
- Published
- 1997-11
- Volume
- 17
- Issue
- 3
- Pages
- 263-264
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1981554609
- Cited by
- 830
- References
- 14
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 27 · 2023: 18 · 2022: 25 · 2021: 19 · 2020: 27 · 2019: 24 · 2018: 16 · 2017: 21 · 2016: 20 · 2015: 19 · 2014: 21 · 2013: 16 · 2012: 20
- FWCI
- 26.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, amyloid-beta, amyloid deposition, Alzheimer's disease, APOE genotype, apolipoprotein E deficiency
- MeSH terms
- Age Factors, Alzheimer Disease, Animals, Apolipoproteins E, Brain, Humans, Immunohistochemistry, Mice, Inbred C57BL, Mice, Inbred DBA, Mice, Transgenic, RNA, Messenger, Polymerase Chain Reaction, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
